Efficacy of VEGFR-TKI plus immune checkpoint inhibitor (ICI) in metastatic renal cell carcinoma (mRCC) patients with favorable IMDC prognosis.

Chiara Ciccarese,Roberto Iacovelli,Emilio Bria,Giovanni Schinzari,Ernesto Rossi,Serena Astore,Maria Antonella Cannella,Tatiana D’Angelo,Carlo Maria Cicala,Maria Grazia Maratta,Giampaolo Tortora

Efficacy of VEGFR-TKI plus immune checkpoint inhibitor (ICI) in metastatic renal cell carcinoma (mRCC) patients with favorable IMDC prognosis.

2021

Chiara Ciccarese
Roberto Iacovelli
Emilio Bria
Giovanni Schinzari
Ernesto Rossi
Serena Astore
Maria Antonella Cannella
Tatiana D’Angelo
Carlo Maria Cicala
Maria Grazia Maratta
Giampaolo Tortora

318Background: Combinations of a PD-1/PD-L1 immune checkpoint inhibitor (ICI) with a VEGFR-TKI as front-line/treatment-naive therapy significantly improve the outcome of metastatic renal cell carci...

Keywords:

Cancer research
immune checkpoint inhibitors
vegfr tki
Renal cell carcinoma
Cell
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations